North Western Hepatobiliary Unit, Aintree University Hospital, Liverpool L9 7AL, United Kingdom; email:
School of Cancer Studies, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3BX, United Kingdom; email:
Annu Rev Med. 2017 Jan 14;68:183-196. doi: 10.1146/annurev-med-062415-093510. Epub 2016 Sep 28.
About 25% of patients with colorectal cancer develop liver metastases after resection of the primary tumor, and surgical resection of the metastases offers the only opportunity for long-term survival. However, only 20% of patients present with resectable disease. Deciding which patients should be offered surgery, and which should receive additional treatment in the form of perioperative chemotherapy, is complex. For the majority of patients who present with technically irresectable liver-limited disease, systemic downsizing chemotherapy offers the only opportunity to reach surgery and potential cure. Molecular analysis of tumor tissue is improving patient stratification, allowing more appropriate treatment selection, but is not yet a regular part of clinical practice. Decision making is limited by a lack of clear prospective evidence, and so multidisciplinary team assessment is essential to optimize outcomes.
约 25%的结直肠癌患者在原发性肿瘤切除术后会发生肝转移,而转移灶的手术切除是获得长期生存的唯一机会。然而,只有 20%的患者为可切除疾病。决定哪些患者应接受手术,哪些患者应接受围手术期化疗等额外治疗是复杂的。对于大多数出现技术上不可切除的肝局限性疾病的患者,全身性缩小化疗是达到手术和潜在治愈的唯一机会。肿瘤组织的分子分析正在改善患者分层,允许更合适的治疗选择,但尚未成为临床实践的常规部分。决策受到缺乏明确前瞻性证据的限制,因此多学科团队评估对于优化结果至关重要。